The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis

BMC Cancer

Lin Qi¹  Chao Tu¹  Zhihong Li¹  Xiaolei Ren¹  Chenghao Zhang¹  Wenchao Zhang¹ 

[1] Department of Orthopedics, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, People’s Republic of China;Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China;

关键词: LncRNAs;    Osteosarcoma;    Meta-analysis;    Prognosis;   

DOI  :  10.1186/s12885-021-07882-w

来源: Springer

【 摘 要 】

BackgroundIn recent years, emerging studies have demonstrated critical functions and potential clinical applications of long non-coding RNA (lncRNA) in osteosarcoma. To further validate the prognostic value of multiple lncRNAs, we have conducted this updated meta-analysis.MethodsLiterature retrieval was conducted by searching PubMed, Web of Science and the Cochrane Library (last update by October 2, 2019). A meta-analysis was performed to explore association between lncRNAs expression and overall survival (OS) of osteosarcoma patients. Relationships between lncRNAs expression and other clinicopathological features were also analyzed respectively.ResultsOverall, 4351 patients from 62 studies were included in this meta-analysis and 25 lncRNAs were identified. Pooled analyses showed that high expression of 14 lncRNAs connoted worse OS, while two lncRNAs were associated with positive outcome. Further, analysis toward osteosarcoma clinicopathologic features demonstrated that overexpression of TUG1 and XIST indicated poor clinical parameters of patients.ConclusionsThis meta-analysis has elucidated the prognostic potential of 16 lncRNAs in human osteosarcoma. Evidently, desperate expression and functional targets of these lncRNAs offer new approaches for prognosis and therapy of osteosarcoma.

【 授权许可】

CC BY